DENVER, CO – June 23, 2025 – AOA Dx (AOA), a company pioneering blood-based diagnostics for early cancer diagnosis, has appointed Dr. Kim Ekroos to its Scientific Advisory Board. As a globally recognized pioneer in lipidomics, Dr. Ekroos will support the scientific development and clinical translation of AOA Dx’s multi-omic diagnostic platform, which integrates lipid-based biomarkers for the early diagnosis of cancer.
Dr. Ekroos has over 20 years of experience in the fields of lipidomics and lipid biology, spanning academic research, biotechnology, and regulatory science. He currently serves as the President of the International Lipidomics Society and is a co-founder of the Lipidomics Standards Initiative, two organizations dedicated to advancing global standards and best practices in the field. Dr. Ekroos is widely credited with shaping the field of lipidomics since its inception, and his work has led to significant advances in both scientific understanding and clinical application, including the first use of lipid-based biomarkers in clinical diagnostics.
“Dr. Ekroos is a remarkable scientist who has been a pioneer in the lipidomics field”. said Abigail McElhinny, Chief Scientific Officer of AOA Dx. “Importantly, his work has bridged the gap between cutting-edge research and real-world clinical utility, particularly in biomarker development. His guidance will be invaluable as we continue to build out our novel multi-omic platform, which leverages lipids and other biomarker classes for earlier, more accurate cancer diagnosis.”
AOA Dx is currently focused on the development of a non-invasive diagnostic for early diagnosis of ovarian cancer, an area of critical unmet need where survival rates remain low due to late-stage diagnosis. By utilizing lipids as a novel biomarker class, in combination with advanced mass spectrometry and multi-omic analysis, AOA Dx aims to revolutionize the early diagnosis landscape and improve outcomes for patients.
“I’m joining AOA Dx’s Scientific Advisory Board to collaborate with a team whose science-first approach to lipidomics is redefining what’s possible in cancer detection.” said Dr. Ekroos. “Lipids offer unique advantages that make them particularly promising for early cancer diagnosis. I’m especially excited about the work AOA Dx is doing in ovarian cancer, and I look forward to supporting their efforts to bring a reliable, non-invasive test to patients who urgently need better diagnostic tools.”
With Dr. Ekroos’s appointment, AOA Dx continues to strengthen its scientific leadership as it advances toward bringing a product to clinics.
About AOA Dx:
AOA Dx is transforming early cancer diagnosis with its proprietary GlycoLocate™ platform, a first-of-its-kind, multi-omics liquid biopsy that integrates gangliosides, lipids, proteins, and clinical data using advanced machine learning. The company’s lead test, AKRIVIS GD™, is designed to diagnosis ovarian cancer early in symptomatic women, where no other diagnostic currently exists. Based in Denver, Colorado, AOA Dx is led by an experienced team of scientists and industry veterans and operates a dedicated lipidomics lab focused on pioneering the future of cancer diagnostics.
About Lipidomics Consulting Ltd:
Lipidomics Consulting Ltd is fundamentally advancing disease biology by providing the cutting-edge experience, skills and know-how in lipids and lipidomics. For more information, visit www.lipidomicsconsulting.com and connect with us on LinkedIn.